June 28, 2022
Obsidian Therapeutics to Participate in the Truist Securities Cell Therapy Symposium
CAMBRIDGE, Mass., June 28, 2022 – Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that management will attend and participate in symposia-cel – a Truist Securities Cell Therapy Symposium. The event will feature in-depth panel discussions and debates, as well as meetings with key opinion leaders and executives from companies at the forefront of cell therapies, and will be held in-person in New York City on June 28, 2022.
Jan ter Meulen, M.D., Ph.D., Chief Scientific Officer of Obsidian, will participate in the panel “Tweaking the TCR Approach”, taking place from 12:15 – 1:00 pm ET. This panel will explore the broad approaches to harnessing this naturally occurring targeting apparatus, both in the form of Tumor Infiltrating Lymphocytes (TIL) therapy as well as engineered TCRs & adaptations.
OBX-115 is Obsidian’s lead cytoTIL15 program, currently in preclinical development for the treatment of patients with metastatic melanoma and other solid tumors. OBX-115 is a novel engineered tumor infiltrating lymphocyte (TIL) therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs, and to deliver enhanced persistence and improved anti-tumor activity. The Company expects to submit an IND for OBX-115 in mid-2022.
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.
Russo Partners, LLC